Medical Device Industry Under the Sino-US Trade War

On October 10, 2025, the US government announced a 100% tariff on all Chinese goods effective November 1. China responded by imposing special port fees on US vessels (effective October 14). The following day, global capital markets reacted swiftly – the S&P 500 index fell 2.1%, and the NASDAQ index plunged 3.4%. Against this backdrop, China proposed easing restrictions on US investments in exchange for a US commitment against Taiwanese independence, but disagreements persist. The escalation of the Sino-US trade war marks the transition of this years-long economic confrontation from a singular tariff conflict into an institutionalized, long-term phase.

For the medical device industry, these fluctuations are more than just a numbers game concerning tariffs. As a highly regulated industry with significant import dependence, its industrial chain is being drawn into a more complex political and economic landscape: rising policy barriers, supply chain restructuring, fluctuating cost structures, and the reallocation of global market confidence. SiYu MedTech notes that the recent "Medical Device Import Safety Investigation" launched by the US government, coupled with the overall downturn in manufacturing sector sentiment, is converging to become the prelude to a new round of systemic risks for the industry.

I. Escalation from "Tariffs" to "Security Reviews": Medical Devices Become Part of "National Security"

In September 2025, the US Department of Commerce formally initiated a dynamic investigation into medical device imports, citing the rationale of "safeguarding national security and the stability of the public health supply chain." According to Reuters, this investigation covers imaging equipment, implantable devices, diagnostic equipment, and their key components.

Extension from Public Health to Geopolitics

New Focus on Technology and Data Security

The future scope of investigations may extend beyond hardware to include emerging digital medical infrastructure such as medical imaging data, AI algorithms, and remote surgery systems.

The US emphasis on "data security and traceability" essentially uses compliance as a pretext to reshape technological competition barriers.

It is widely believed within the industry that this new pressure tool, added by the Trump administration under the "national security + tariffs" framework, aims to preset the path for more targeted tariff policies or import restrictions in the next stage through administrative review means.

The medical device industry is characterized by high barriers to entry and low profit margins. Any policy fluctuation can directly impact product prices, hospital procurement cycles, and patient treatment costs. The strengthening of these "non-tariff barriers" subjects the global medical supply system to greater uncertainty. For the United States, this is about redefining import dependency in the name of security; for China and other manufacturing countries, it means comprehensively increasing regulatory pressure concerning technology, quality certification, and certificates of origin.

II. Industry Performance: Waning US Capital Confidence, Medical Devices Become a High-Risk Sector

The second major impact of the trade war is evident in the capital markets.

Since 2025, the US healthcare sector (including medical devices, consumables, diagnostics, and services) within the S&P framework has underperformed the broader market, declining approximately 5% year-on-year by September (Reuters data).

Analysis suggests this trend stems from three factors:

Policy uncertainty coupled with tariff expectations has led markets to generally lower profit margin assumptions for medical device companies;

Rising cyclical risks in the supply chain make investment institutions inclined to avoid productive manufacturing links;

Declining expectations for industry financing and innovation are driving capital towards sectors with lower policy risks, such as digital health and AI healthcare.

Stock volatility among medical device companies also reflects the industry's structural anxiety. Given the industry's long investment cycles, significant R&D expenditures, and slow return periods, short-term capital outflows are more pronounced in an environment of tightening macro-policies and capital.

Analysts point out that this "policy-driven valuation volatility" may become the new normal – a company's competitiveness will depend not only on technological innovation but also on its sustainable operational capacity within the global policy system.

III. Supply Chain and Manufacturing End: Hidden Costs and Structural Contraction

The latest manufacturing PMI data shows the US manufacturing index fell to 49.1 in September 2025, entering contraction territory. The manufacturing slowdown implies that upstream enterprises – including suppliers of precision machinery, sensors, optics, materials, and motors – will all be affected.

The production cycle of medical equipment relies on the stable supply of these intermediate components. Therefore, when overall manufacturing cools down, medical device manufacturers face rising hidden costs in procurement, delivery, and inventory management.